Intellia Therapeutics

Intellia Therapeutics is a clinical-stage genome editing company that develops potentially curative therapies using CRISPR/Cas9 technology. It pursues both in vivo programs, in which editing happens inside the body, and ex vivo programs. Its lead candidates include nexiguran ziclumeran (NTLA-2001) for transthyretin (ATTR) amyloidosis and lonvoguran ziclumeran (NTLA-2002) for hereditary angioedema.